IBB small-caps outperform
In the small-cap space by market cap, the iShares Nasdaq Biotechnology ETF (IBB) outperformed the top ten small-cap stocks of the SPDR S&P Biotech ETF (XBI) for the week ended September 4, 2015. The IBB top ten small-cap stocks returned -0.32%, while the XBI top ten mid-cap stocks returned -3.82%% for the same period.
The above graph reflects the performance comparison of the top ten small-cap stocks of IBB and XBI. The IBB top ten small-caps outperformed the IBB itself as well as the top ten large-cap stocks, which include stocks such as Gilead Sciences (GILD), Amgen (AMGN), and Celgene (CELG).
Theravance and Alder help IBB small-caps
Theravance (THRX) rose 15.70% for the week ended September 4, 2015. According to the press release, THRX is presenting at two investor conferences in September 2015. The stock closed at $15.99 on September 4 and is trading just below the 100-day moving averages. THRX has a weight of 0.29% in IBB.
Alder BioPharmaceuticals (ALDR) rose 5%. According to the press release, ALDR presented at the Wells Fargo 2015 Healthcare Conference in Boston. The stock closed at $40.54 on September 4, 2015, and was trading below the 50-day and 100-day moving averages. Alder has a weight of 1.64% in XBI and 0.23% in IBB.
The biggest fall came from Ariad Pharmaceuticals (ARIA). The stock fell 19.41% since Baxalta’s bid to take over ARIA fell apart. The stock closed at $7.97 on September 4 and was trading below the 20-day, 50-day, and 100-day moving averages.